The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity

Slides:



Advertisements
Similar presentations
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
Advertisements

Molecular Therapy - Oncolytics
Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors
Avoiding Immune Detection
Immunotherapy of hepatocellular carcinoma
Antigen-Primed CD8+ T Cells Call DCs for Back Up
Specific Defenses of the Host: The Immune Response
CD5: A New Partner for IL-6
Tumor Microenvironment: No Effector T Cells without Dendritic Cells
Cancer Immunotherapy by Dendritic Cells
The role of viruses in acute exacerbations of asthma
Differentiation and Functions of CD8+ Effector T Cells
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
The Th17 immune response in renal inflammation
From Oncogene Interference to Neutrophil Immune Modulation
Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial  Max Heckler, Stephanie.
The Lymphopenic Mouse in Immunology: From Patron to Pariah
Some DCs Are “B”etter Immunity
Roles for Chemokines in Liver Disease
Malaria Vaccine Design: Immunological Considerations
Taking T Cell Priming Down a Notch: Signaling through Notch Receptors Enhances T Cell Sensitivity to Antigen  Timothy J. Thauland, Manish J. Butte  Immunity 
Colorectal cancer vaccines: Principles, results, and perspectives
Nicholas van Bruggen, Wenjun Ouyang  Immunity 
Molecular Therapy - Oncolytics
Volume 44, Issue 6, Pages (June 2016)
Does CSF1R Blockade Turn into Friendly Fire?
Georges Makhoul, MD, MS, Ray C.J. Chiu, MD, PhD, Renzo Cecere, MD, MS 
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
Laurence Zitvogel, Guido Kroemer  Cancer Cell 
The Multitasking Organ: Recent Insights into Skin Immune Function
Intracellular Pathogens and CD8+ Dendritic Cells: Dangerous Liaisons
Arming Treg Cells at the Inflammatory Site
Like Parent, Like Child: Inheritance of Effector CD8+ T Cell Traits
Volume 20, Issue 5, Pages (May 2012)
Interleukin-17 Kick-Starts T Helper 1 Cell Differentiation
The 3 major types of innate and adaptive cell-mediated effector immunity  Francesco Annunziato, PhD, Chiara Romagnani, MD, PhD, Sergio Romagnani, MD  Journal.
The Multitasking Organ: Recent Insights into Skin Immune Function
Pro-endometriotic niche in endometriosis
Langerhans Cells Orchestrate TFH-Dependent Humoral Immunity
TH17 and TH22 cells: A confusion of antimicrobial response with tissue inflammation versus protection  Mübeccel Akdis, MD, PhD, Oscar Palomares, PhD,
Volume 25, Issue 1, Pages (January 2014)
John T. Chang, William J. Sandborn  Gastroenterology 
An IL-1β-Dependent Switch in Innate Mucosal Immunity?
Designing Vaccines Based on Biology of Human Dendritic Cell Subsets
Vaccinating Against Helicobacter pylori: Dissecting the Mechanism
CD8 T Cells and IFN-γ Emerge as Critical Players for Psoriasis in a Novel Model of Mouse Psoriasiform Skin Inflammation  Paola Di Meglio, João H. Duarte 
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
Figure 1 Sequence of events in the development of autoimmune nephritis
A View to Natural Killer Cells in Hepatitis C
Adiponectin: an enlarging role in acute kidney injury
Maria Rescigno, Iliyan D. Iliev  Gastroenterology 
A Role for Th17 Cells in the Immunopathogenesis of Atopic Dermatitis?
Deciphering and Reversing Tumor Immune Suppression
Monocyte-Macrophages and T Cells in Atherosclerosis
A New “Immunological” Role for Adipocytes in Obesity
Revisiting the role of B cells in skin immune surveillance
HGF Guides T Cells into the Heart
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Basophils and mast cells in renal injury
Defining the Antigen Determinant for T-Cell-Mediated Contact Dermatitis Using p- Phenylenediamine: A Gateway to Chemical Immunology  Graham Elliott, Pranab.
Vaccines for Lung Cancer
Volume 44, Issue 6, Pages (June 2016)
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?
Some DCs Are “B”etter Immunity
Intratumoral CD4+ T Lymphodepletion Sensitizes Poorly Immunogenic Melanomas to Immunotherapy with an OX40 Agonist  Susumu Fujiwara, Hiroshi Nagai, Noriko.
Cytokine Gene Therapy for Malignant Pleural Mesothelioma
Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy  Robert D. Leone, Maureen R. Horton, Jonathan D.
Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
CTLA4Ig: Bridging the Basic Immunology with Clinical Application
Presentation transcript:

The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity Jan P. Böttcher, Caetano Reis e Sousa  Trends in Cancer  Volume 4, Issue 11, Pages 784-792 (November 2018) DOI: 10.1016/j.trecan.2018.09.001 Copyright © 2018 Francis Crick Institute Terms and Conditions

Figure 1 Orchestration of Cancer Immune Control by cDC1. Conventional type 1 dendritic cells (cDC1s) are recruited into the tumor microenvironment by chemokines such as XCL1 and CCL5, produced by intratumoral natural killer (NK) cells (and potentially other lymphocytes). NK cells further secrete the growth factor FLT3L, which supports the survival of cDC1s and might enhance local cDC1 differentiation from DC precursors. Within the tumor, cDC1s take up material from (dead?) tumor cells and are uniquely able to transport tumor antigens to tumor-draining lymph nodes for presentation to naive CD8+ T cells, priming cytotoxic effector CD8+ T cells. In addition, cDC1s within the tumor microenvironment produce the chemokines CXCL9/10 that can recruit CD8+ effector T cells into tumor tissue and can locally present tumor antigens to restimulate recruited T cells. Finally, the anti-tumor activity of T cells and NK cells within the tumor might further be boosted by cytokines made by cDC1, for example, interleukin-12 (IL-12), that, in turn, is amplified by T- and NK cell–derived cytokines such as interferon-γ (IFN-γ). Trends in Cancer 2018 4, 784-792DOI: (10.1016/j.trecan.2018.09.001) Copyright © 2018 Francis Crick Institute Terms and Conditions